MRSN250117C5000
- 0.03
- 0.000.00%
Mersana Therapeutics Newsroom
Truist Financial Maintains Mersana Therapeutics(MRSN.US) With Buy Rating
BTIG Maintains Mersana Therapeutics(MRSN.US) With Buy Rating, Maintains Target Price $6
Buy Rating for Mersana Therapeutics: Promising Efficacy and Safety of Emi-Le ADC Amid Stock Price Volatility
Wedbush Cuts Price Target on Mersana Therapeutics to $4 From $7, Keeps Outperform Rating
LifeSci Capital Maintains Mersana Therapeutics(MRSN.US) With Buy Rating, Maintains Target Price $8
BTIG Maintains Mersana Therapeutics(MRSN.US) With Buy Rating, Maintains Target Price $6
Citi Maintains Mersana Therapeutics(MRSN.US) With Buy Rating, Cuts Target Price to $5
Analysts Offer Insights on Healthcare Companies: ACELYRIN, INC. (SLRN), Cabaletta Bio (CABA) and Mersana Therapeutics (MRSN)
Truist Financial Maintains Mersana Therapeutics(MRSN.US) With Buy Rating
A Quick Look at Today's Ratings for Mersana Therapeutics(MRSN.US), With a Forecast Between $6 to $8
TD Cowen Remains a Buy on Mersana Therapeutics (MRSN)
LifeSci Capital Maintains Mersana Therapeutics(MRSN.US) With Buy Rating, Maintains Target Price $8
Truist Financial Maintains Mersana Therapeutics(MRSN.US) With Buy Rating
LifeSci Capital Maintains Mersana Therapeutics(MRSN.US) With Buy Rating, Maintains Target Price $8
Buy Rating for Mersana Therapeutics: Promising ADC Developments and Strategic Market Positioning
Truist Financial Maintains Mersana Therapeutics(MRSN.US) With Buy Rating
Truist Financial Maintains Mersana Therapeutics(MRSN.US) With Buy Rating, Announces Target Price $9
Truist Financial Sticks to Its Buy Rating for Mersana Therapeutics (MRSN)
Mersana Therapeutics Is Maintained at Buy by Citigroup
Mersana Therapeutics Price Target Cut to $5.00/Share From $6.00 by Citigroup